08/09/2026 Imfinzi + Imdelltra demonstrated significant benefit in 1st‑line ES‑SCLC maintenance In registrational Phase 2 QUINTESSENTIAL trial, GPRC5D CAR T therapy (arlo‑cel) achieved significant ORR improvement in heavily pretreated multiple myeloma INBRX‑106 + pembrolizumab elicited strong ORR signal in Phase 2 part of Ph2/3 HexAgon-HN trial, driving expansion and FDA‑aligned path to Phase 3 confirmatory trial in HNSCC Imfinzi + Imdelltra demonstrated significant benefit i

27/01/2026 Johnson & Johnson's DARZALEX FASPRO regimen has been approved in the US for multiple myeloma Imviva Biotech's CTD402 CAR-T received the FDA orphan drug designation for T-ALL/LBL Nanjing Leads Biolabs' LBL-034 received the FDA fast track designation for multiple myeloma Johnson & Johnson's DARZALEX FASPRO regimen has been approved in the US for multiple myeloma (Ref) The US FDA granted approval to Johnson & Johnson's DARZALEX FASPRO (daratumumab and hyaluronidase-fi

30/07/2025 Phase 3 COSTAR Lung trial of dostarlimab + docetaxel ± cobolimab failed to meet the OS endpoint in previously treated NSCLC (Ref) GSK's Phase 3 COSTAR Lung/NCT04655976 trial of dostarlimab (anti-PD-1) + docetaxel ± cobolimab (anti-TIM-3) combinations did not meet the primary endpoint of improving OS vs docetaxel alone in advanced NSCLC that has progressed on prior PD-(L)1 therapy and chemotherapy. All regimens were well tolerated and toxicities were consistent with